Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 16/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23746042 | 0.99 | FOLH1 (0.69) | FOLH1SLC6A3EPHX1 | |
| SCHEMBL11977615 | 0.93 | FOLH1 (0.84) | FOLH1 | |
| SCHEMBL11977608 | 0.93 | FOLH1 (0.84) | FOLH1 | |
| SCHEMBL23077794 | 0.92 | FOLH1 (0.82) | FOLH1 | |
| SCHEMBL20312082 | 0.92 | FOLH1 (0.63) | FOLH1SLC6A3 | |
| SCHEMBL11977610 | 0.91 | FOLH1 (0.71) | FOLH1 | |
| SCHEMBL11977640 | 0.89 | FOLH1 (0.56) | FOLH1SLC6A3EPHX1 | |
| SCHEMBL23746034 | 0.85 | FOLH1 (0.72) | FOLH1 | |
| Mip-1095 I-123 SCHEMBL17558049 | 0.83 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL11977611 | 0.83 | FOLH1 (0.70) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10647666-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10640461-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190276393-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20180111895-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111895-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-9878980-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878980-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9309193-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309193-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2942065-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8487129-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487129-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885SLC6A3 438/4885EPHX1 2497/4885 |
| US-20190276393-A1 | Heterodimers of Glutamic Acid | GLUL, DDO, ASNS | FOLH1 4/4885SLC6A3 518/4885EPHX1 2391/4885 |
| US-10647666-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | FOLH1 5/4885SLC6A3 438/4885EPHX1 2497/4885 |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | FOLH1 5/4885SLC6A3 449/4885EPHX1 2487/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885SLC6A3 438/4885EPHX1 2497/4885 |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885SLC6A3 440/4885EPHX1 2490/4885 |
| US-10640461-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | FOLH1 5/4885SLC6A3 438/4885EPHX1 2497/4885 |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | FOLH1 5/4885SLC6A3 394/4885EPHX1 2530/4885 |
| US-20180111895-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | FOLH1 5/4885SLC6A3 459/4885EPHX1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.